JP6469518B2 - 血管新生促進剤 - Google Patents
血管新生促進剤 Download PDFInfo
- Publication number
- JP6469518B2 JP6469518B2 JP2015099488A JP2015099488A JP6469518B2 JP 6469518 B2 JP6469518 B2 JP 6469518B2 JP 2015099488 A JP2015099488 A JP 2015099488A JP 2015099488 A JP2015099488 A JP 2015099488A JP 6469518 B2 JP6469518 B2 JP 6469518B2
- Authority
- JP
- Japan
- Prior art keywords
- angiogenesis
- amylin
- huvecs
- cells
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000033115 angiogenesis Effects 0.000 title description 31
- 238000011282 treatment Methods 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 6
- 206010052428 Wound Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 3
- 230000003779 hair growth Effects 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 241000161997 Hieracium plumulosum Species 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 claims 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 claims 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 claims 1
- 229940069445 licorice extract Drugs 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 26
- 238000000605 extraction Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000001737 promoting effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 210000003556 vascular endothelial cell Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000009471 action Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 9
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- -1 aliphatic alcohols Chemical class 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 241000694401 Acer maximowiczianum Species 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241001143500 Aceraceae Species 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 238000002738 Giemsa staining Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本実施形態の血管新生促進剤は、β−アミリンを有効成分として含有するものである。
ヒト臍帯静脈内皮細胞(HUVECs;Cambrex Bio Science Walkersville社より購入)に対する増殖促進作用の検討は、Premix WST-1 Cell Proliferation Assay System(タカラバイオ社製)を用い、製品添付の試験方法に従って行った。具体的には、HUVECsを、内皮細胞基礎培地(EBM−2;Clonetics社製)に増殖因子であるEGM−2添加剤(EBM−2に付属)を添加した培地を用い、37℃、5%CO2条件下で培養した。得られたHUVECsを1×104cells/wellとなるよう96ウェルプレートに播種して4時間培養し、被験試料(試料1,最終濃度は0.025,0.25,1または10μM)を添加し、更に24,48または72時間培養した。各時点でPremix WST-1溶液(タカラバイオ社製)を添加し、マイクロプレートリーダー(BioRad社製)を用いて440nmの波長の吸光度を測定した。得られた各データは平均値±標準偏差で示した。
HUVECsの管腔形成促進作用試験は、成長因子の含有量の少ないマトリゲル(BD Biosciences社製)を用いて従来の方法で試験を行った。具体的には、HUVECsを、EGM−2添加剤を添加したEBM−2培地を用い、37℃、5%CO2条件下で培養した。その後、HUVECsをEBM−2培地にてさらに15時間培養し、血清飢餓状態とした。これを5×104cells/cm2になるようマトリゲルコートプレート(BD Biosciences社製)上に播種し、被験試料(試料1,最終濃度は0.025または1μM)を含有するEBM−2培地で6時間培養した。培養したプレート上の細胞を、位相差顕微鏡(オリンパス社製)にて、40倍の倍率で撮影した。管腔形成能の程度は、無作為に撮影した5つの顕微鏡画像を用い、形成された管腔の長さを画像解析ソフトであるImage-Jを用いて評価した。この操作を3回繰り返した。得られた各データは平均値±標準偏差で示し、2集団間の差についてスチューデントt検定を行った。多集団間での比較は片側ANOVAによって検定を行い、p<0.05であるものを有意差があると判定した。
HUVECsを、EGM−2添加剤を添加したEBM−2培地を用い、37℃、5%CO2条件下で培養した。その後、被験試料(試料1,最終濃度は0.025または1μM)存在下でさらに30分培養した。培養終了後、RIPA細胞溶解液(Thermo Scientific社製)で溶解し、この細胞溶解液をイムノブロットに用いた。抗体は抗Akt、抗リン酸化Akt(Ser473)、抗eNOS、抗リン酸化eNOS(Ser1177)、およびコントロールとしての抗β-アクチンの各抗体(いずれもCell Signaling Technology社製)を用いた。得られた結果について、シグナル強度を画像解析ソフトであるImage-Jを用いて数値化し、試験例2と同様に統計処理を行った。
β−アミリン(試料1)の血管内皮細胞(HUVECs)に対する作用について、Akt阻害剤であるLY294002(Calbiochem社より購入)およびNOS阻害剤であるL−NAME(Sigma Chemical社より購入)を用い、Akt−eNOSシグナル経路の関与の有無を評価した。
Claims (2)
- β−アミリン(ヒエラシウム・プルムロサム A.カーナー(Hieracium plumulosum A. Kerner)抽出物または甘草抽出物に含まれるβ−アミリンを除く)を有効成分とすることを特徴とする血管新生促進剤。
- 創傷の治療または改善用途、血流の改善用途、むくみの予防または改善用途、目の下のクマの予防または改善用途、および育毛用途からなる群より選択される少なくとも一つの用途に使用されることを特徴とする請求項1に記載の血管新生促進剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015099488A JP6469518B2 (ja) | 2015-05-14 | 2015-05-14 | 血管新生促進剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015099488A JP6469518B2 (ja) | 2015-05-14 | 2015-05-14 | 血管新生促進剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016216375A JP2016216375A (ja) | 2016-12-22 |
JP6469518B2 true JP6469518B2 (ja) | 2019-02-13 |
Family
ID=57580217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015099488A Active JP6469518B2 (ja) | 2015-05-14 | 2015-05-14 | 血管新生促進剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6469518B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4134132A4 (en) | 2020-04-08 | 2023-09-13 | Ichimaru Pharcos Co., Ltd. | UNIT TO PROMOTE ANGIOGENESIS AND/OR NERVE REGENERATION |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379714B1 (en) * | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
JP4076296B2 (ja) * | 1999-01-22 | 2008-04-16 | 株式会社ナリス化粧品 | 化粧料 |
CN101431989B (zh) * | 2005-12-30 | 2011-11-23 | 雷文斯治疗公司 | 局部给药的精氨酸杂聚体 |
JP2011132203A (ja) * | 2009-12-25 | 2011-07-07 | Imy:Kk | 保湿用化粧料シート |
JP6491202B2 (ja) * | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | サイクリン依存性キナーゼ7(cdk7)の多環阻害剤 |
-
2015
- 2015-05-14 JP JP2015099488A patent/JP6469518B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016216375A (ja) | 2016-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013023487A (ja) | 抗糖化作用剤 | |
JP5990058B2 (ja) | エストロゲン受容体β活性化剤 | |
JP4969849B2 (ja) | NF−κB活性化抑制剤、及びこれを含有する外用剤組成物II | |
JP6469518B2 (ja) | 血管新生促進剤 | |
JP6240626B2 (ja) | 抗アトピー性皮膚炎用組成物 | |
KR102033073B1 (ko) | 세리신, 사상자 추출물 및 겨우살이 추출물을 포함하는, 피부 재생, 진정 또는 상처 치유용 조성물 | |
EP4230214A1 (en) | Composition for preventing and treating anti-inflammatory and autoimmune diseases and non-alcoholic fatty liver disease, comprising extract derived from centipeda minima | |
JP5496951B2 (ja) | 血小板由来成長因子(pdgf)−bb産生亢進剤、及びそれを含む幹細胞安定化剤 | |
JP2005239660A (ja) | 前駆脂肪細胞分化促進剤 | |
KR102085052B1 (ko) | 식물 추출물을 포함하는 피부 항염 또는 피부 보습용 조성물 | |
JP5836421B2 (ja) | 育毛組成物、毛乳頭細胞増殖促進組成物、fgf−7産生促進組成物、vegf産生促進組成物、及び膚表面血流促進組成物並びに化粧料 | |
JP2000344630A (ja) | 育毛剤原料及びその精製方法並びに育毛剤組成物 | |
JP4083111B2 (ja) | β−エンドルフィン産生促進剤 | |
JP2002284648A (ja) | 育毛剤組成物 | |
JP6026257B2 (ja) | セラミド産生促進剤 | |
JP2011111416A (ja) | セマフォリン発現増強剤 | |
JP7315940B2 (ja) | 線維芽細胞増殖因子-5発現抑制剤 | |
JP5992661B2 (ja) | ヒアルロン酸産生促進剤 | |
JP2019108278A (ja) | しわ改善剤 | |
JP2011026240A (ja) | 花粉荷を含有する育毛剤 | |
JP6002510B2 (ja) | エストロゲン受容体β活性化剤 | |
TWI842129B (zh) | 一種菊花萃取物及其用於製備抑制發炎反應和促進傷口癒合的醫藥組合物之用途 | |
JP7286131B2 (ja) | 糖尿病性潰瘍の治癒促進剤 | |
JP6017259B2 (ja) | エンドセリン作用抑制剤 | |
JP2018108973A (ja) | Xvii型コラーゲン産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181225 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6469518 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |